NO983474L - Expression of Group B Neisseria meningitidis outer membrane (MB3) protein from yeast and vaccines - Google Patents

Expression of Group B Neisseria meningitidis outer membrane (MB3) protein from yeast and vaccines

Info

Publication number
NO983474L
NO983474L NO983474A NO983474A NO983474L NO 983474 L NO983474 L NO 983474L NO 983474 A NO983474 A NO 983474A NO 983474 A NO983474 A NO 983474A NO 983474 L NO983474 L NO 983474L
Authority
NO
Norway
Prior art keywords
group
protein
yeast
outer membrane
meningococcal
Prior art date
Application number
NO983474A
Other languages
Norwegian (no)
Other versions
NO983474D0 (en
Inventor
Joseph Y Tai
Michail Donets
Ming-Der Wang
Shu-Mei Liang
Marvellen Palvino-Bodnar
Conceicao A S A Minetti
Francis Michon
Original Assignee
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine Inc filed Critical North American Vaccine Inc
Publication of NO983474D0 publication Critical patent/NO983474D0/en
Publication of NO983474L publication Critical patent/NO983474L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det er beskrevet en fremgangsmåte for oppnåelse av ytre membranprotein meningococcal gruppe B porin proteiner, spesielt MB3, og fusjonsproteiner derav. Det er spesielt beskrevet en fremgangsmåte for uttrykking av ytre membranprotein meningococcal gruppe B porin proteiner i gjær. Det er også beskrevet en fremgangsmåte for ekspresjon i høyt nivå av ovennevnte proteiner hvori raten til proteinekspresjon blir forsterket ved substituering av en nukleotidsekvens til 5' regionen av genet kodende for nevnte protein hvori sekvensen er blitt optimalisert for gjærkodonbruk. Det er videre beskrevet en vaksine omfattende gruppe A meningococcal polysakkarid (GAMP), gruppe B meningococcal polysakkarid (GBMP) og gruppe C meningococcal polysakkarid (GCMP) antigener, sammen med en farmasøytisk akseptabel bærer. Det er også beskrevet en fremgangsmåte for indusering av en immunrespons i et pattedyr omfattende administrering av ovennevnte vaksine til pattedyr i en mengde som er tilstrekkelig for å indusere en immunrespons.A method for obtaining outer membrane protein meningococcal group B porin proteins, in particular MB3, and fusion proteins thereof is disclosed. In particular, a method for expressing the outer membrane protein meningococcal group B porin proteins in yeast is disclosed. Also described is a high-level expression method of the above proteins wherein the rate of protein expression is enhanced by substituting a nucleotide sequence into the 5 'region of the gene encoding said protein in which the sequence has been optimized for yeast codon use. A vaccine comprising Group A meningococcal polysaccharide (GAMP), Group B meningococcal polysaccharide (GBMP) and Group C meningococcal polysaccharide (GCMP) antigens, together with a pharmaceutically acceptable carrier, is further described. There is also disclosed a method of inducing an immune response in a mammal comprising administering the aforementioned vaccine to mammals in an amount sufficient to induce an immune response.

NO983474A 1996-02-01 1998-07-28 Expression of Group B Neisseria meningitidis outer membrane (MB3) protein from yeast and vaccines NO983474L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1097296P 1996-02-01 1996-02-01
US2044096P 1996-06-13 1996-06-13
PCT/US1997/001687 WO1997028273A1 (en) 1996-02-01 1997-01-31 Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines

Publications (2)

Publication Number Publication Date
NO983474D0 NO983474D0 (en) 1998-07-28
NO983474L true NO983474L (en) 1998-09-30

Family

ID=26681820

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983474A NO983474L (en) 1996-02-01 1998-07-28 Expression of Group B Neisseria meningitidis outer membrane (MB3) protein from yeast and vaccines

Country Status (9)

Country Link
EP (1) EP0877816A1 (en)
JP (1) JP2001508758A (en)
KR (1) KR19990082265A (en)
AU (1) AU2115897A (en)
HU (1) HUP9901039A2 (en)
IL (1) IL125420A0 (en)
NO (1) NO983474L (en)
PL (1) PL328096A1 (en)
WO (1) WO1997028273A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1272062A (en) 1997-07-17 2000-11-01 北美疫苗公司 Immunogenic conjugates comprising group meningococcal porin and an i (H. influenzae) polysaccharide
NZ508366A (en) 1998-05-01 2004-03-26 Chiron Corp Neisseria meningitidis antigens and compositions
DE69927375T2 (en) * 1998-07-06 2006-06-22 Tosoh Corp., Shinnanyo FUSION PROTEIN WITH DIRECT LINKING OF IL-6 RECEPTOR WITH IL-6
JP4524816B2 (en) * 1998-07-06 2010-08-18 東ソー株式会社 IL-6 receptor / IL-6 direct fusion protein
GB9818004D0 (en) * 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
JP2003518363A (en) 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． Conserved Neisseria antigen
AU781469B2 (en) 1999-05-13 2005-05-26 Wyeth Holdings Corporation Adjuvant combination formulations
NZ545647A (en) 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
EP1069133A1 (en) * 1999-07-13 2001-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neisseria meningitidis compounds and anti-infection applications thereof
DK1741784T3 (en) * 1999-11-29 2010-05-25 Novartis Vaccines & Diagnostic 85kDa antigen from neisseria
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT1248647E (en) 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
CN1800385B (en) 2000-02-28 2010-06-02 启龙有限公司 Hybrid expression of neisserial proteins
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
DK1549338T3 (en) 2002-10-11 2011-03-28 Novartis Vaccines & Diagnostic Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
EP1587537B1 (en) 2003-01-30 2012-04-11 Novartis AG Injectable vaccines against multiple meningococcal serogroups
JP2006262846A (en) * 2005-03-25 2006-10-05 Niigata Bio Research Park Kk Method for synthesizing and purifying 2-deoxy-scyllo-inosose with yeast and obtained 2-deoxy-scyllo-inosose
KR100919704B1 (en) * 2007-09-12 2009-10-06 한국생명공학연구원 An Effective Method for Expressing and Secreting Recombinant Proteins in Yeast
JP2011116658A (en) * 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst Manufacturing method of medicine for swine atrophic rhinitis
US9974848B2 (en) 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines
CN106146679B (en) * 2015-04-23 2019-02-01 中国医学科学院医学生物学研究所 A kind of method of purification of bacterial capsular polysaccharide
NZ737094A (en) 2015-05-11 2019-06-28 Impossible Foods Inc Expression constructs and methods of genetically engineering methylotrophic yeast
JP2019500041A (en) * 2015-12-30 2019-01-10 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． Partial enzymatic hydrolysis of triacylglycerol.
AU2020257270A1 (en) 2019-04-17 2021-11-18 Impossible Foods Inc. Materials and methods for protein production

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5268273A (en) * 1990-12-14 1993-12-07 Phillips Petroleum Company Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising same
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis

Also Published As

Publication number Publication date
WO1997028273A1 (en) 1997-08-07
IL125420A0 (en) 1999-03-12
AU2115897A (en) 1997-08-22
KR19990082265A (en) 1999-11-25
JP2001508758A (en) 2001-07-03
PL328096A1 (en) 1999-01-04
NO983474D0 (en) 1998-07-28
EP0877816A1 (en) 1998-11-18
HUP9901039A2 (en) 1999-07-28

Similar Documents

Publication Publication Date Title
NO983474L (en) Expression of Group B Neisseria meningitidis outer membrane (MB3) protein from yeast and vaccines
Matsuo et al. Establishment of a foreign antigen secretion system in mycobacteria
Ellis Vaccines: New approaches to immunological problems
JP4827196B2 (en) Domains and epitopes of meningococcal protein NMB1870
Ellis New technologies for making vaccines
EP0863211A1 (en) Expression of recombinant fusion proteins in attenuated bacteria
US9579375B2 (en) Chimeric poly peptides and the therapeutic use thereof against a Flaviviridae infection
CA1338705C (en) Vaccines obtained from antigenic gene products of recombinant genes
JPH03502687A (en) Respiratory syncytial viruses: vaccines and diagnostics
GB9224584D0 (en) Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
EP1126874A2 (en) Multicomponent meningococcal vaccine
CA2623540A1 (en) Dampening of an immunodominant epitope of an antigen for use in plant, animal and human vaccines and immunotherapies
Taubman et al. Diepitopic construct of functionally and epitopically complementary peptides enhances immunogenicity, reactivity with glucosyltransferase, and protection from dental caries
US7902349B2 (en) Nucleic acids encoding protective epitopes of adenyl cyclase-haemolysin (AC-Hly)
WO2022003119A1 (en) Cross-reactive coronavirus vaccine
ES2236718T3 (en) CARRIER PROTEIN OF ADJUTIVE EFFECT, IMMUNOGENIC COMPLEX CONTAINING IT, ITS PREPARATION PROCEDURE, NUCLEOTIDIC SEQUENCE AND VACCINE.
US7169399B2 (en) Non-toxic double mutant forms of pertussis toxin as adjuvants
Guillén et al. Expression in Escherichia coli of the lpdA gene, protein sequence analysis and immunological characterization of the P64k protein from Neisseria meningitidis
JP2011103893A (en) Recombinant haemophilus influenzae adhesin protein
JPH05213995A (en) Amino acid residue arrangement of hepatitis b virus core antigen
JPS6117523A (en) Broad spectrum vaccine for gonorrhoea
NO20005081L (en) A polypeptide comprising the amino acid of an N-terminal choline binding protein A truncate, vaccine derived therefrom and uses thereof
EP0320866A2 (en) A protective immunodominant epitope included in the S1 subunit of pertussis toxin
CN104945513B (en) Streptococcus mutans cell surface protein antigen (SpaP) and glucosyltransferase (GtfB) amalgamation protein vaccine and preparation method thereof
Chen et al. A nontoxic Pseudomonas exotoxin A induces active immunity and passive protective antibody against Pseudomonas exotoxin A intoxication